Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 14/20 | 0.46 |
| ▸ | CA2 | P00918 | 14/20 | 0.46 |
| ▸ | CA4 | P22748 | 8/20 | 0.46 |
| ▸ | CA9 | Q16790 | 8/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA3 | P07451 | 3/20 | 0.46 |
| ▸ | CA6 | P23280 | 3/20 | 0.46 |
| ▸ | CA5A | P35218 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CA11 | O75493 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13711902 | 0.81 | CA1 (0.69) | CA1CA2CA4CA9CA12 | |
| SCHEMBL17320001 | 0.80 | CA1 (0.56) | CA1CA2CA4CA9CA12 | |
| SCHEMBL18656466 | 0.68 | CA1 (0.68) | CA1CA2CA4CA9CA12 | |
| SCHEMBL11930741 | 0.63 | CA1 (0.76) | CA1CA2CA4CA9CA12 | |
| SCHEMBL10797173 | 0.63 | CA1 (1.00) | CA1CA2CA4CA9CA12 | |
| SCHEMBL11840140 | 0.62 | CA1 (0.72) | CA1CA2CA4CA9CA12 | |
| SCHEMBL11566691 | 0.60 | CA1 (0.69) | CA1CA2CA4CA9CA12 | |
| SCHEMBL11929008 | 0.60 | CA1 (0.69) | CA1CA2CA4CA9CA12 | |
| SCHEMBL3501152 | 0.60 | CA1 (0.69) | CA1CA2CA4CA9CA12 | |
| SCHEMBL14501008 | 0.60 | CA2 (0.58) | CA1CA2CA4CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605178-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080119538-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119538-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, GOT1 | CA1 1953/4885CA2 1184/4885CA4 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.